Navigation Links
Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China
Date:5/9/2011

BETHLEHEM, Pa., QUEENSLAND, Australia and BEIJING, May 9, 2011 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today the formation of its Pacific Rim commercialization team to expand its presence in Australia and China.

Members of Saladax's Pacific Rim commercialization team include:

  • Yunying Li, Ph.D. (Saladax Biomedical, Inc.) – Dr. Li, Director of Market Development, Asia, with Saladax Biomedical, has held leadership roles in the Company since 2004.  Until 2010, she served as Research Group Leader, supervising product development efforts of the MyCare™ assay development group.  Prior to Saladax, Dr. Li was a senior research scientist at OraSure Technologies, Inc.  Dr. Li has relocated to Beijing where, utilizing her technical experience with the MyCare line and her cultural ties in China, she will lead the establishment of Saladax's commercial presence in this important market.  

  • Patrick Cook (Macarthur Cook Group Pty Ltd) – Mr. Cook is Principal at Macarthur Cook Group Pty Ltd, a privately held company in Queensland, Australia, which provides business development, education and training services.  Mr. Cook's extensive experience in the Australian diagnostic industry will help Saladax expand its sales and marketing efforts in Australia.  Mr. Cook serves as director and board member of IVD Australia Ltd., a leader in Australia's in vitro diagnostic industry.  He has worked with multiple international and local organizations including Roche Diagnostics, Quidel, Abbott Diagnostics and Royal Brisbane & Women's Hospital.

"With Dr. Li's extensive experience working with Saladax and Mr. Cook's significant knowledge and recognition in the diagnostics industry, we are confident we will successfully commercialize Saladax's assays in China and Australia," said Edward L. Erickson, president and CEO of Saladax.  

About Saladax Biomedical, Inc.

Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics.  The Company's dose management technology enables physicians to optimize drug dosing to meet individual patient needs, leading to improved response and quality of life.  The Company's 15 MyCare™ dose management assays are comprised of proprietary, automated and cost-effective in vitro diagnostic tests, with a principal focus in oncology.  The first MyCare assay available is for one of the most common anticancer drugs, 5-fluorouracil (5-FU).  This assay is available in the United States from Myriad Genetics, sold by Saladax in Europe and will be distributed in Japan by FALCO biosystems.  Saladax also works with pharmaceutical companies to develop companion diagnostics to provide important clinical information to assist in developing and administering new and existing compounds.

Saladax Biomedical, Inc.
Adrienne Choma, Esq.
VP Marketing & Sales
achoma@saladax.com

Media Contact:
Tiberend Strategic Advisors, Inc.
212-827-0020
Andrew Mielach
amielach@tiberend.com
or
Farrell Denby
fdenby@tiberend.com


'/>"/>
SOURCE Saladax Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
2. Binder Biomedical, Inc. Announces the Release of the X-GRAFT(TM) Interspinous Device, as Part of Their QUANTUM(TM) Line of Spinal Allograft Devices, Manufactured at the University of Miami Tissue Bank
3. BINDER BIOMEDICAL, INC. Announces Official Launch of the NEWTON™ Intervertebral Body Fusion Spinal Spacer System
4. Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc. Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... Summary Breast cancer, a malignant neoplasm, ... common cancer in women worldwide, accounting for 16% of ... number of women diagnosed with breast cancer has increased ... deaths has declined due to earlier diagnosis and better ... in the past four decades, especially with increasing usage ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Identifying and Commercializing First-in-Class Innovation ... disorder associated with chronic inflammation of the airways ... of COPD symptoms make the disease one of ... cause of death in the world. COPD is ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... February 06, 2016 , ... ... eating disorder treatment helps to reduce the frequency and level of relapse. ... Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of the ...
(Date:2/5/2016)... & Salt Lake City, UT (PRWEB) , ... February 05, 2016 ... ... of Activz Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi ... New Really Cool Humans Amateur TV Network. , Each week, on his weekly Whole-Food ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
(Date:2/5/2016)... ... 2016 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Event at the La Gorce Country Club in Miami Beach on March 15, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the routine: each January, ... to access the treadmills. It’s a predictable trend. After the excesses of November and ... in shape by joining gyms, starting new walking or running routines, or signing up ...
Breaking Medicine News(10 mins):